SKIN heads into its May 7 earnings date with short sellers still building and analysts cutting targets — a combination that frames the upcoming print as a genuine test of the bull case.
Short interest has been climbing persistently all year. At 25.5% of the free float, short positions have risen from roughly 22.6% at the start of the data window in late March to a new high this week — a grind higher rather than an aggressive spike, but relentless in direction. The week itself added about 0.7 percentage points, with short shares rising 2.7% over seven days. Availability has tightened in parallel: the ratio of shares available to borrow against those already borrowed has dropped from around 145% in late March to 117% now, indicating the lending pool is becoming less spacious as demand for borrows grows. Borrow cost remains cheap at 0.79% APR — not distressed — but availability continuing to tighten into earnings is a pattern worth watching. The ORTEX short score of 82.2 ranks in the 2nd percentile of the short interest universe, placing SKIN among the most heavily shorted names on the platform.
Options traders, by contrast, are not stacking protection. The put/call ratio has collapsed to 0.13, well below its 20-day average of 0.17, and sits near the low end of its 52-week range (low: 0.04, high: 0.70). That's unusual: shorts are building while options players show no appetite for hedges. The disconnect suggests the options market sees a contained downside scenario even as bearish positioning in shares grows.
The Street's direction is uniformly cautious. Every analyst carrying the name has a Hold rating, and recent moves have been reductions. Canaccord's Susan Anderson trimmed her target to $1.00 on May 1 — the freshest action and the most pessimistic on record — after maintaining at $1.50 in March. TD Cowen cut to $1.50 in mid-March. The mean target now sits at $1.61, roughly 86% above the current price of $0.86, but that gap reflects target cuts that have lagged the stock's decline rather than genuine upside conviction. The bear case is well-articulated: core delivery system placements fell more than 30% year-over-year last quarter, and China demand remains a drag on the delivery-system segment. The bull case rests on consumables resilience — U.S. spend per treatment rose 10% year-over-year — and improving EMEA performance, up 9.3%.
Institutional ownership adds a layer of complexity. Linden Manager LLC holds 26% of shares outstanding and made no change in the most recent filing period. Capricorn Fund Managers is the second-largest holder at 15%, having entered the position entirely in the quarter ended March — a new significant stake worth watching for follow-on filings. FMR (Fidelity) holds another 14%. Between those three, over half the float is effectively anchored, which limits the stock's theoretical squeeze potential despite the high short interest. Insider activity tells a one-sided story: the COO, CFO, and CEO equivalent have all been steady sellers across March and April, at prices ranging from $1.17 down to $0.92 — a consistent signal from those closest to the business.
Historically, SKIN has responded sharply to earnings. The March quarter print produced a one-day gain of roughly 13%, with the five-day follow-through fading to about 7%. The prior event registered identically. Whether the next print carries the same dynamic depends on whether the consumables growth narrative holds against weakening delivery system numbers.
What to watch on May 7: delivery system placement trends in China, any change to full-year guidance, and whether the lending market tightens further following the print — availability at current levels leaves room to run before the borrow becomes genuinely difficult.
See the live data behind this article on ORTEX.
Open SKIN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
